Still, developing novel targeted pharmacological or genetically centered (i.e., RNA-based) approaches with a focus on SRB1 may improve liver damage occurring in MASLD [33,34]. This evidence concerns the gene SCARB1 and metabolic dysfunction-associated steatotic liver disease.